Trial Profile
A phase II, open label, single arm study to assess the efficacy of AZD9291 in patients with locally advanced/metastatic non-small cell lung cancer who are harboring T790M mutation detected by liquid biopsy and whose disease has progressed with previous epidermal growth factor receptor tyrosine kinase inhibitor therapy(WJOG8815L)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 May 2020
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 29 Apr 2020 Status changed from active, no longer recruiting to completed.
- 04 Jun 2018 Status changed from recruiting to active, no longer recruiting.
- 25 Oct 2016 Status changed from not yet recruiting to recruiting.